![](/local/images/2022/products/detail/bg_mobile.jpg)
news
![](/upload/iblock/d77/2n0nj5ic8zdr2u7fv2jzt8yvl93u8qpk/111.jpg)
Experts presented various data generated from studies investigating the Russian drug Longidaza® when used in patients with residual pulmonary abnormalities after COVID-19 at the 21st Century Pulmonology National Congress held in Moscow.
![](/upload/resize_cache/iblock/f7f/x7ke0c791iu2v8e0m4co99rlqj2i6ruf/350_250_1/novost-2.jpg)
![](/upload/iblock/78c/nisdhcgbzh8mvu7j6o6t601k4p625wft/anons.jpg)
![](/upload/resize_cache/iblock/329/6lby2jb9437m0vdmt5a68e2p8t13lub8/350_250_1/11.jpg)
![](/upload/resize_cache/iblock/f18/b8gbhgnh1ehfnrtuwd9lxrnhxyzsfvfk/350_250_1/Dobavleny-2-foto.jpeg)
![](/upload/resize_cache/iblock/5a9/gbeign4mg9gp1qckzsyz5rdbztzuofgo/350_250_1/97fda5b97b2fb8e4c7fcc721254fca06.jpg)
![](/upload/resize_cache/iblock/53f/kf9bfmt7ob4n3u85q1ekequ5xdsiz9do/350_250_1/izobrazhenie_1_fyjyc.png)
![](/upload/resize_cache/iblock/74c/gjkezvjkxbk2hgvg6j72x5z36h8621uy/350_250_1/Urologicheskaya_shkola.JPG_anons.jpg)
Experts presented various data generated from studies investigating the Russian drug Longidaza® when used in patients with residual pulmonary abnormalities after COVID-19 at the 21st Century Pulmonology National Congress held in Moscow.
This site contains information for medical and pharmaceutical professionals.
To view the content, please, confirm that you have the appropriate qualifications.